default author photo

Katie Flanagan

University of Tasmania - School of Health Sciences and School of Medicine

SCHOLARLY PAPERS

4

DOWNLOADS

315

TOTAL CITATIONS

3

Scholarly Papers (4)

1.

The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old

Number of pages: 39 Posted: 08 Jul 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 116 (613,149)
Citation 1

Abstract:

Loading...

COVID-19, Booster Vaccines, Immunogenicity, adaptive platform trial, health policy.

2.

The Platform Trial in COVID-19 Priming and Boosting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Different COVID-19 Vaccinations Administered as a Second Booster (Fourth Dose) in Azd1222 Primed Individuals Aged 50-<70 Years Old

Number of pages: 13 Posted: 07 May 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 110 (640,165)

Abstract:

Loading...

Adaptive platform trial, COVID-19, vaccines, Bayesian, immunisation, policy

3.

Robust and Prototypical Immune Responses Towards Influenza Vaccines in the High-Risk Group of Indigenous Australians

Number of pages: 51 Posted: 17 Feb 2021
University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection and Immunity, World Health Organisation (WHO) Collaborating Centre for Reference and Research on Influenza, at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Charles Darwin University - Menzies School of Health Research, Charles Darwin University - Menzies School of Health Research, Charles Darwin University - Menzies School of Health Research, Charles Darwin University - Menzies School of Health Research, Menzies School of Health Research and Charles Darwin University, Burnet Institute, Burnet Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Indigenous Engagement, CQ University, University of Melbourne - Department of Microbiology and Immunology (DMI), Menzies School of Health Research and Charles Darwin University, Menzies School of Health Research and Charles Darwin University, University of Melbourne - Peter Doherty Institute for Infection and Immunity and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 52 (1,041,696)

Abstract:

Loading...

4.

SARS-CoV-2 Infection in Children Does Not Necessitate Establishment of Adaptive SARS- CoV-2-Specific Immunological Memory

Number of pages: 49 Posted: 04 Nov 2021
University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Infection and Immunity, Monash University - Infection and Immunity Program and Department of Biochemistry and Molecular Biology, St. Jude Children’s Research Hospital - Department of Immunology, University of Melbourne - Department of Microbiology and Immunology, St. Jude Children's Research Hospital - Department of Immunology, St. Jude Children's Research Hospital - Department of Immunology, Monash University - Infection and Immunity Program, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), Icahn School of Medicine at Mount Sinai - Department of Microbiology, Icahn School of Medicine at Mount Sinai - Department of Microbiology, University of Tasmania - School of Medicine, University of Tasmania - School of Health Sciences and School of Medicine, University of Melbourne - Murdoch Children's Research Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Monash University - Infection and Immunity Program, St. Jude Children’s Research Hospital - Department of Immunology, University of Melbourne - Department of General Medicine, University of Melbourne - Infection and Immunity, University of Melbourne - Department of Microbiology and Immunology (DMI) and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 37 (1,222,651)
Citation 2

Abstract:

Loading...

COVID-19, T cells, B cells, seroconversion, children, memory T cells